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Abstract
Background: Multiple therapeutic strategies to restore immune regulation and slow type 1 diabetes (T1D) progression are in development and testing. A major challenge has been defining biomarkers to prospectively identify subjects likely to benefit from immunotherapy and/or measure intervention effects. We previously found that compared to healthy controls, Tregs from children with new-onset T1D have an altered Treg gene signature (TGS), suggesting this could be an immunoregulatory biomarker. Results: Compared to controls, the TGS in isolated Tregs or PBMCs is altered in adult new-onset and cross-sectional T1D cohorts, with sensitivity and specificity of biomarkers increased by including T1D-associated single nucleotide polymorphisms in algorithms. The TGS was distinct in T1D versus type 2 diabetes, indicating disease-specific alterations. TGS measurement at the time of T1D onset revealed an algorithm that accurately predicted future rapid versus slow Cpeptide decline, as determined by longitudinal analysis of placebo arms of START and T1DAL trials. The same algorithm stratified participants in a phase I/II clinical trial of ustekinumab (aIL-12/23p40) for future rapid versus slow C-peptide decline.
Conclusion: These data suggest that biomarkers based on measuring Treg gene signatures could be a new approach to stratify patients and monitor autoimmune activity in T1D.
Introduction
Insufficient FOXP3 + regulatory T cell (Treg) control of T cell-mediated destruction of beta-cells likely contributes to type 1 diabetes (T1D) (1) . Monogenic mutations in FOXP3 resulting in a lack of functional Tregs lead to T1D (2) and several T1D risk alleles occur in Treg-associated genes (e.g. single nucleotide polymorphisms [SNPs] in CD25, PTPN2 and PTPN22) (1) .
Accordingly, multiple studies are testing whether immunotherapy-based methods to boost Treg function can prevent or delay T1D progression (1, 3, 4) . For example, inflammatory cytokine blockade (e.g. ustekinumab, aIL-12/23p40 (5)), co-stimulation targeting (e.g. alefacept, LFA3-4-Ig (6)), or Treg expansion (e.g. low-dose IL-2; cellular therapy (7, 8) ) aim to restore the immunoregulatory balance. However, availability of clinically-applicable tests to measure changes in immunity during such trials is limited (3), with an on-going search for biomarkers to stratify patients likely to respond to a given therapy and track changes in immune regulation (4, 9) .
We previously developed a composite biomarker assay which measures expression of 37 genes and discriminates between Tregs and conventional T cells (Tconvs) regardless of activation state and showed that Tregs from pediatric new onset T1D patients have a significantly altered gene signature (10) . Here we tested whether Treg gene signatures (TGS)
could also identify Treg alterations in adults with T1D and investigated the predictive power of TGS-based biomarkers to predict the rate of C-peptide decline.
Results

Adults with T1D have an altered Treg gene signature in sorted Tregs and PBMCs
We previously found that pediatric new onset T1D Tregs had a significantly different TGS compared to healthy children (10) and first tested if this was also true in adults. Tregs (CD4  + CD25 hi CD127 lo ) were isolated from young adults with new onset T1D (18-35 years of age, <100 days after diagnosis, n=20, Figure 1A) , a cross-sectional T1D cohort ((9), n=40, Figure 1B ), or age-and sex-matched healthy controls (HC, n=10 or n=37). Expression of the TGS was measured using a nCounter FLEX and biomarker discovery analysis applied. We found the TGS distinguished between T1D and healthy Tregs with high AUCs [area under the receiving operating characteristic curves] in both cohorts ( Figure 1A&B , AUC=0.830, =0.953).
Cut-offs for sensitivity (true positives) and specificity (true negatives) determination were set between 0.25 and 0.75, revealing high sensitivity and specificity for both cohorts.
Genetic risk alleles including SNPs in CD25, PTPN2 and PTPN22 are associated with CD25 expression, response to IL-2, FOXP3 stability, and Treg function in T1D (1). We thus hypothesized that genotype information might refine biomarker accuracy. Biomarker discovery using the cross-sectional T1D cohort and including genotype(s) revealed that while overall AUCs were similar to those obtained without genotype, there was slightly improved sensitivity in several cases ( Figure 2 ). For example, adding CD25 rs2104286 number of disease variants
[NDV] improved the sensitivity from 0.875 ( Figure 1B ) to 0.950 ( Figure 2C ), but overall inclusion of SNPs only modestly improved accurate discrimination between healthy and T1D
Tregs.
Clinical application of biomarker tests should ideally entail minimal sample processing to simplify implementation, reduce processing errors, and increase reproducibility. We therefore next examined whether differential TGS expression could be detected in unfractionated PBMCs.
Gene expression in PBMC lysates from adult new onset (n=19, Figure 3A ) and cross-sectional (n=35, Figure 3B ) T1D cohorts, and age-and sex-matched controls (HC, n=10 or n=38) were measured and biomarker discovery analysis applied. Surprisingly, gene expression in PBMC lysates also revealed highly sensitive and specific algorithms that discriminated between healthy controls and new onset or cross-sectional T1D cohorts (AUC= 0.895, =0.977, respectively).
Adding genotype information to biomarker discovery generated near perfect classification of T1D versus HCs with most AUCs, sensitivity and specificity >0.900 ( Figure 4) . Thus, the inclusion of Treg-associated SNPs is valuable when assessing changes in the overall immunoregulatory balance by measuring the TGS in PBMC lysates.
Differences in gene usage between Treg and PBMC-derived algorithms
The varying number and identity of genes in each best-performing algorithm led us to compare gene usage across algorithms derived from Tregs versus PBMCs in the cross-sectional T1D cohort ( Figure 5 ). We found that there were 10 core genes in all of the best performing algorithms derived from sorted Tregs ( Figure 5A ). These included genes associated with DNA accessibility (METTL7A, a methyltransferase), transcription (ZNF532, VAV3, RBMS3), translation (RPL23A, a ribosomal protein), signal transduction (VAV3, TCR mediated signalling (11)), and cytokine receptors (CSF2RB, IL1R1, IL7R).
Examination of the PBMC-based algorithm also revealed 10 core genes (
Figure 5B In contrast, IL1RN and RPL23A were always present in both Treg-and PBMC-based algorithms.
Hence, PBMC-based algorithms may detect changes in Treg to Tconv ratios which are eliminated when analysing TGS of sorted Tregs.
Treg gene signature algorithms in type 1 versus type 2 diabetes
TGS changes could be related to poor glucose homeostasis rather than a change in immune regulation. We thus measured the TGS in sorted Tregs or PBMCs from type 2 diabetes (T2D) patients, and re-ran the age-and sex-matched T1D and HC lysates in parallel, in this case using the nCounter SPRINT system. Principle Components Analysis (PCA) was performed separately on Treg and PBMC data to highlight differences between patients (i.e. HC vs T1D vs T2D) rather than reiterate differences present between sample types (i.e. Tregs vs PBMCs). Analysis of the unweighted TGS revealed distinct clustering of T2D, T1D and HCs for both Treg and PBMC samples ( Figure 6 ).
For these experiments, since we re-ran T1D and HC cohort samples from Figures 1&3 with the T2D samples on the nCounter SPRINT system we also had to opportunity to test T1D versus HC algorithms from Figure 1B "off-the-shelf", finding excellent replication of the AUC (=1.000) and, without changing cut-offs, perfect sensitivity (=1.000) but low specificity (=0.222, Figure 7A ). New biomarker analysis comparing T1D to T2D, or T2D to HC using Treg lysates also revealed algorithms that were highly sensitive and specific (AUCs >0.9, Figure 7B&C ).
Similar results were obtained when PBMC lysates were analysed. "Off-the-shelf" application of the algorithm from Figure 3B 
Application of the Treg gene signature as clinical trial monitoring tool.
A limitation of T1D disease management and clinical trials is the lack of non-invasive biomarkers to predict C-peptide trajectory and measure intervention benefit (9) . Hence, we asked whether the TGS might predict disease trajectory. Together with the JDRF Biomarker Working
Group and the Immune Tolerance Network, we obtained longitudinal samples from the placebo arms of the T1DAL and START trials (9) . Subjects were divided into tertiles with slow, moderate or rapid C-peptide decline, as determined by mixed meal tolerance tests (MMTTs), according to absolute change in C-peptide levels from baseline (<100 days after diagnosis) to 24 months later ( Figure 8A )
We measured the TGS in Treg and PBMC lysates from month 0 samples and performed biomarker discovery, seeking an algorithm that could predict future rapid versus slow C-peptide decline. Although the sample size was small (n=7 rapid vs 9 slow decline), the TGS in Treg ZBTB38 also showed trends in line with C-peptide decline. In contrast, biomarker analysis of PBMC lysates was ineffective at discriminating between these groups (data not shown),
suggesting that Treg-intrinsic alterations rather than an overall change in immunoregulatory balance may be better able to predict future disease course.
Finally, we tested if the TGS could predict C-peptide decline in the setting of immunotherapy. Specifically, we used samples from a phase I/II safety trial of ustekinumab (aIL-12/23 p40) in adult new onset T1D (NCT02117765). Ustekinumab is commonly used in psoriasis and inflammatory bowel disease (12) , and its ability to block IL-12 and IL-23 might restore the abnormal balance of T helper subsets, and/or IL-17-producing Tregs that we (13) and others (14, 15) previously described in T1D. C-peptide was measured by MMTTs pre-treatment (month 0), and at 1 and 12 months after ustekinumab treatment. Subjects were divided into slow (n=11) or rapid (n=5) C-peptide decline based on reported expected rates of decline (16) ( Figure   9A ). We first applied the unmodified algorithm from Figure 8B "off-the-shelf" to pre-treatment Treg gene expression data finding this algorithm prospectively identified rapid versus slow Cpeptide decline with AUC=0.709; however, the specificity was low (=0.182, Figure 9B ), indicating that cut-offs for sensitivity/specificity calculations need refinement.
We then asked whether the TGS changed over the course of ustekinumab therapy by dividing month 9 Treg gene expression data by pre-treatment (month 0) data. Biomarker discovery revealed excellent predictive models (AUC=0.818, sensitivity=0.909 and specificity=0.800) that identified subjects with slow versus rapid C-peptide decline ( Figure 9C ).
Evidence that the algorithm improved when both pre-treatment and month 9 data were included suggests that subjects with sustained versus rapidly declining C-peptide may have differing ustekinumab-driven changes in their TGS. As with the non-interventional longitudinal samples, algorithms based on month 0 PBMC lysates were ineffective (data not shown).
Finally, the TGS at month 9 could also differentiate between slow and rapid C-peptide decline ( Figure 9D&E) . Interestingly, at this time point both Treg and PBMC-derived signatures yielded good algorithms (AUCs=0.900 and =0.745, respectively, Figure 9D&E ). These data suggest that the TGS may detect ustekinumab-mediated changes in Treg-intrinsic gene expression and in the balance between Tregs and Tconvs upon immunotherapy. We found some gene usage overlap with algorithms described in previous Figures ( Figure 9F ).
Discussion
Here we build on our previous finding that Tregs from children with new-onset T1D have an altered TGS and show that this is also true in adult new-onset and cross-sectional T1D cohorts.
The altered T1D TGS did not appear to be determined to changes in glucose homeostasis as analysis of samples from subjects with type 2 diabetes revealed no overlap in gene expression profiles. We also showed the potential of TGS monitoring as a biomarker of disease trajectory, possibly enabling patient stratification for immunotherapy and monitoring of therapy outcomes.
TGS measurement is simple, requires very small amounts of blood and integrates multiple aspects of Treg biology that would be difficult to quantify in individual assays.
Our biomarker discovery approach utilized a leave one out cross validation approach to identify algorithms with high AUCs, sensitivity and specificity for each comparison of interest with the resulting algorithms typically only including a subset of the 37 quantified transcripts. Despite small sample sizes, we found that the TGS may be a novel approach to the longstanding challenge of predicting and measuring T1D disease trajectory and intervention effects on the immunoregulatory balance. Specifically, application of a single TGS algorithm in two independent cohorts was able to identify the majority of new onset T1D subjects whose Cpeptide was likely to decline rapidly. Interestingly, pre-existing changes in Tregs seemed to correlate with future disease trajectory after ustekinumab treatment. These findings may indicate that a Treg-specific defect, instead of an immunoregulatory-imbalance, dictates future disease course. Our data also suggest possible differential ustekinumab-mediated intrinsic effects on
Tregs and the immunoregulatory-balance in subjects with rapid versus slow C-peptide decline.
Overall these data indicate that further testing of TGS-based algorithms in larger cohorts is warranted.
To date, only two other studies have reported prognostic biomarkers after T1D onset.
Hessner et al measured changes in PBMC gene expression upon culture in T1D plasma (17) , finding that patients with higher inflammatory signature at baseline had slower C-peptide decline in response to IL-1RA in the AIDA trial (NCT00711503). Similarly, Linsley et al employed whole blood RNA-sequencing to find an increased T cell signature early after rituximab (NCT00279305) in patients with rapid C-peptide decline after 1 year (18) . Compared to these large "omic" based approaches, nanoString-based TGS measurement requires very few cells (<10,000) and minimal processing, making it easier to test in validation studies and more clinically feasible. As our understanding of T1D evolves from a linear to a relapsing-remitting autoimmunity model (19) , it will be of interest to continue measuring the TGS prospectively over time, including before disease diagnosis, to determine if it may enable real-time evaluation of autoimmune activity.
In conclusion, these findings suggest that measuring Treg gene signatures could be a step towards a biomarker of immune status in T1D. Future application of our findings across multiple studies together with development of a cross-platform and cross-chemistry standardization workflow may lead to the development of "universal" algorithms that could be applied to identify rapid vs slow progressors, monitor T1D over time, and/or select subjects likely to respond to immunotherapy. Tables T1-5 Tables T6 & T7) . Sorted Tregs and PBMCs were both lysed in RLT lysis buffer (Qiagen) at 3,500-5,000 cells/µL.
Methods
Sample collection and cell isolation. Peripheral blood from each cohort was obtained and cryopreserved as PBMCs (Supplemental
nanoString analysis. mRNA expression was measured in 2µL Treg/PBMC lysates with a custom nCounter reporter probe set on nanoString nCounter FLEX or SPRINT systems. Sample quality was assessed by cartridge-specific normalization factors and positive control linearity.
Gene expression data were normalized in four steps: 1) multiplication by sample's normalization factor (geometric mean of positive controls divided by median); 2) total sum normalization equalling 5000 counts; 3) log2 transformation; and 4) ComBat batch correction (20) . Each cohort, PBMCs or Tregs were batch-corrected separately.
Statistics. Analyses were performed using R (21) and GraphPad Prism V8. Biomarker discovery analysis included 31 TGS genes (10) plus 6 genes differentially expressed between healthy and T1D. Differential expression was assessed using LiMMa (22) with p-value threshold of 0.1.
Binary classifiers were built using logistic or elastic net regression (23), with a=0.65 (10) or =0.9. Where genotypes were available, the number of disease variant alleles (NDV) for each patient (either for a single SNP, or all eight SNPs tested) was included in the analysis as a covariate. Leave-one-out cross-validation was used to obtain performance estimates (area under the receiving operating characteristic curve (AUC), sensitivity, and specificity). For each 13 comparison, the best algorithm was selected on the basis of the highest AUC. To define sensitivity (true positive) and specificity (true negative), the definition of the cut-off for samples falling into one group versus another was set between 0.25 and 0.75 and is indicated by a dotted line on each biomarker score graph.
Comparison of two groups was performed by unpaired t-test (referenced in text, data not shown) and of multiple groups was performed by one-way ANOVA with Tukey's multiple comparisons test ( Figure 8C ) and a p value of 0.05 was considered significant (data in 8C was not significantly different) using GraphPad Prism V8. Figure 3B and 4. Each of the 37 mRNAs measured is listed, grey and white squares indicate genes which were or were not present in the best performing algorithm, respectively. lo Tregs and PBMCs from the indicated age-and sex-matched cohorts using the nCounter SPRINT system. For Tregs: T2D n=29, T1D n=7, and healthy controls (HC) n=9. For PBMCs: T2D n=33, T1D n=10, and healthy controls n=9. Shown is a principal component analysis representing expression of all 37 genes by sample group in (A) Tregs or (B) PBMCs. 95% confidence intervals are overlaid as ellipses. Figure 3B was applied to T1D and healthy control PBMC data. (E&F) Biomarker scores and details (as described in Figure 1&3 ) of the best biomarker algorithm differentiating between (E) T1D or (F) control and T2D samples in PBMCs. Horizontal lines represent means with SD as error bars; dashed horizontal lines represent cut-offs for sensitivity and specificity calculations. (G&H) Summary of gene usage in each (G) Treg or (H) PBMC-based algorithm described in A-F. Each of the 37 mRNAs measured is listed, grey and white squares indicate genes which were or were not present in the best performing algorithm, respectively. ) were sorted from cryopreserved PBMCs isolated from these subjects at baseline (M0) and the TGS was measured. (B) Biomarker score and details (as described in Figure 1&3 ) of the best algorithm predicting future rapid, slow, or moderate C-peptide decline. Horizontal lines represent means with SD as error bars; dashed horizontal lines represent cut-offs for sensitivity and specificity calculations. (C) Expression of the indicated genes plotted by rate of C-peptide decline group, with one-way ANOVA with Tukey's multiple comparisons test (* p-value £0.05, but data not significantly different). 
